---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-381899"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2026-09-03T20:12:25+00:00"
generated_at: "2026-09-03T20:13:32.949074+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Teva reports $500M duvakitug milestone, $2.2B debt issuance, and $29.6B goodwill impairment

## Summary
- $500M milestone received in Q4 2025 for duvakitug Phase 3 initiation; $500M upfront in Q4 2023.
- Issued $700M 5.75% notes due 2030, €1B 4.125% due 2031, $500M 6.00% due 2032 in May 2025.
- Tender offer extinguished $1.579B of 3.15% notes due 2026 and other notes; $10M loss recorded.
- Cumulative goodwill impairment stable at $29.6B as of Dec 31, 2025 and 2024.
- Repaid $1.812B of senior notes maturing in 2025 during the year.

## SEC filing metadata
- accession: 0001193125-26-381899
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2026-09-03T20:12:25+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/0001193125-26-381899-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-381899
- JSON: https://secwatch.observer/filing/0001193125-26-381899.json
- Plain text: https://secwatch.observer/filing/0001193125-26-381899.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.